Clevidipine warnings and precautions
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Warnings and Precautions
5.1 Need for Aseptic Technique
Use aseptic technique and discard any unused product within 12 hours of stopper puncture [see Dosage and Administration (2.3)].
5.2 Hypotension and Reflex Tachycardia
Cleviprex may produce systemic hypotension and reflex tachycardia. If either occurs, decrease the dose of Cleviprex. There is limited experience with short-duration therapy with beta-blockers as a treatment for Cleviprex-induced tachycardia. Beta-blocker use for this purpose is not recommended.
5.3 Lipid Intake
Cleviprex contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism. For these patients, a reduction in the quantity of concurrently administered lipids may be necessary to compensate for the amount of lipid infused as part of the Cleviprex formulation.
5.4 Negative Inotropy
Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.
5.5 Beta-Blocker Withdrawal
Cleviprex is not a beta-blocker, does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.
5.6 Rebound Hypertension
Patients who receive prolonged Cleviprex infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.
5.7 Pheochromocytoma
There is no information to guide use of Cleviprex in treating hypertension associated with pheochromocytoma.[1]
References
- ↑ "CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY]". Retrieved 27 February 2014.